AbbVie drops transparency fight

被引：0
作者：
Gunjan Sinha
机构：
来源：
Nature Biotechnology | 2014年 / 32卷 / 6期
关键词：
D O I：
10.1038/nbt0614-507b
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：507 / 507
相关论文
共 50 条
[41]   NEUROSCIENCE AbbVie gets rights to acquire Mitokinin [J].
Cross, Ryan .
CHEMICAL & ENGINEERING NEWS, 2021, 99 (08) :13-13
[42]   AbbVie invests in pioneering celiac disease therapy [J].
Sarah Crunkhorn .
Nature Reviews Drug Discovery, 2013, 12 :497-497
[43]   ONCOLOGY AbbVie, TeneoOne ink immunotherapy deal [J].
Jarvis, Lisa .
CHEMICAL & ENGINEERING NEWS, 2019, 97 (07) :17-17
[44]   AbbVie invests in Alector's immunoneurology therapies [J].
Cross, Ryan .
CHEMICAL & ENGINEERING NEWS, 2017, 95 (43) :9-9
[45]   AbbVie and Voyager form Parkinson's pact [J].
Cross, Ryan .
CHEMICAL & ENGINEERING NEWS, 2019, 97 (09) :13-13
[46]   AbbVie invests in pioneering celiac disease therapy [J].
Crunkhorn, Sarah .
NATURE REVIEWS DRUG DISCOVERY, 2013, 12 (07) :497-497
[47]   Fight, fight, fight! [J].
Fletcher, Kim .
BRITISH JOURNALISM REVIEW, 2021, 32 (02) :14-15
[48]   Fight, fight, fight [J].
Hooper, Rowan .
NEW SCIENTIST, 2018, 238 (3180) :24-25
[49]   AbbVie pays $21 billion for Pharmacyclics' BTK inhibitor [J].
Asher Mullard .
Nature Reviews Drug Discovery, 2015, 14 :227-227
[50]   AbbVie pays $21 billion for Pharmacyclics' BTK inhibitor [J].
Mullard, Asher .
NATURE REVIEWS DRUG DISCOVERY, 2015, 14 (04) :228-228
12345